# ExCell Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/excell-bio

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.excellbio.com
- Total disclosed funding: $60M
- Latest round: Series B (May 10, 2023)
- Investors on record: 14

## About

Established in 2013 and based in Shanghai, China, ExCell Bio is a biological reagent company that provides medical material and technology services and was a member of the International Serum Industry Association (ISIA). ExCell Bio has several offices in Beijing, Guangzhou, Hong Kong, etc, and several branches in the United States, Australia, Uruguay, etc. In May 2023, it raised approximately CNY 100 million in series B+ funding.

ExCell Bio provides products and services for customers in the fields of biomedicine, cell gene therapy, and stem cell industry. The products include serum-free culture medium, fetal bovine serum, and functional identification kits. It also provides one-stop solutions such as biopharming solutions, cell/gene therapy solutions, stem cell therapy solutions, and vaccine solutions.

## Funding rounds

- Series B, May 10, 2023, $14M — Shenzhen Investment Holdings, Shanghai GP Xinpeng Investment Management, Hainan Puen Zhongjian Private Equity Fund Management, ABC International Capital
- Series B, Jan 7, 2023, $15M — China International Capital Corporation, State Science & Technology Investment, Asia America Multi-Technology Association, Cherish Capital, Haiwang Capital
- Series B, Oct 26, 2021, $16M — MPC
- Series B, Oct 12, 2020, $15M — Yonghua Capital, Asia America Multi-Technology Association, Zhongfa Advanced Capital, Yaobin Technology
- Series A, Dec 2, 2016 — Yonghua Capital, Yanyuan Innovation Investment

## Investors

- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A, Series B
- Yanyuan Innovation Investment (https://capitalatlas.ai/funds/yanyuan-innovation-investment) — Series A
- Asia America Multi-Technology Association — Series B
- Zhongfa Advanced Capital (https://capitalatlas.ai/funds/zhongfa-advanced-capital) — Series B
- Yaobin Technology — Series B
- MPC — Series B
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series B
- State Science & Technology Investment (https://capitalatlas.ai/funds/state-science-technology-investment) — Series B
- Cherish Capital (https://capitalatlas.ai/funds/cherish-capital) — Series B
- Haiwang Capital (https://capitalatlas.ai/funds/haiwang-capital) — Series B
- Shenzhen Investment Holdings — Series B
- Shanghai GP Xinpeng Investment Management — Series B
- Hainan Puen Zhongjian Private Equity Fund Management — Series B
- ABC International Capital (https://capitalatlas.ai/funds/abc-international-capital) — Series B